Eli Lilly and Company

163.87+0.5700+0.35%Vol 1.96M1Y Perf 43.66%
Jul 2nd, 2020 16:02 DELAYED
BID163.88 ASK165.39
Open164.07 Previous Close163.30
Pre-Market- After-Market163.87
 - -%  - -%
Target Price
173.50 
Analyst Rating
Moderate Buy 1.67
Potential %
5.88 
Finscreener Ranking
     42.76
Insiders Trans % 3/6/12 mo.
-100/-100/-52 
Value Ranking
     41.88
Insiders Value % 3/6/12 mo.
-100/-100/-87 
Growth Ranking
★★★★     57.75
Insiders Shares Cnt. % 3/6/12 mo.
-100/-100/-84 
Income Ranking
     31.62
Market Cap156.73B 
Earnings Rating
Sell
Price Range Ratio 52W %
94.61 
Earnings Date
30th Jul 2020

Today's Price Range

162.37164.77

52W Range

101.36167.43

Summary:

Buy

Technical Indicators: Buy
Moving Averages: Strong Buy
Performance
1 Week
0.68%
1 Month
8.73%
3 Months
17.33%
6 Months
24.36%
1 Year
43.66%
3 Years
98.15%
5 Years
92.60%
10 Years
500.73%

TickerPriceChg.Chg.%
LLY163.870.57000.35
AAPL368.514.40001.21
GOOG1 464.7026.66001.85
MSFT206.261.56000.76
XOM44.080.37000.85
WFC25.340.25001.00
JNJ140.970.59000.42
FB233.42-4.1300-1.74
GE6.820.08001.19
JPM92.66-0.6000-0.64
Financial StrengthValueIndustryS&P 500US Markets
0.60
1.10
0.82
5.60
16.30
Leverage Ratio 13.20
ProfitabilityValueIndustryS&P 500US Markets
79.20
28.70
33.70
15.70
23.97
RevenueValueIndustryS&P 500US Markets
23.09B
24.14
1.20
3.59
DividendsValueIndustryS&P 500US Markets
1.82
2.96
8.13
5.42
Payout ratio52.00
Earnings HistoryEstimateReportedSurprise %
Q01 20201.551.7512.90
Q04 20191.521.7313.82
Q03 20191.431.483.50
Q02 20191.461.502.74
Q01 20191.321.330.76
Q04 20181.361.33-2.21
Q03 20181.371.391.46
Q02 20181.311.5014.50
Earnings Per EndEstimateRevision %Trend
6/2020 QR1.58-7.60Negative
9/2020 QR1.780.56Positive
12/2020 FY6.820.74Positive
12/2021 FY8.011.01Positive
Next Report Date30th Jul 2020
Estimated EPS Next Report1.58
Estimates Count4
EPS Growth Next 5 Years %15.80
Volume Overview
Volume1.96M
Shares Outstanding956.45M
Trades Count24.56K
Dollar Volume371.53M
Avg. Volume4.30M
Avg. Weekly Volume2.95M
Avg. Monthly Volume4.33M
Avg. Quarterly Volume3.79M

Eli Lilly and Company (NYSE: LLY) stock closed at 163.87 per share at the end of the most recent trading day (a 0.35% change compared to the prior day closing price) with a volume of 1.96M shares and market capitalization of 156.73B. Is a component of S&P 500, Russell 1000 indices and it is traded on NYSE exchange. The company belongs in the Drug Manufacturers industry, Healthcare sector and employs 38680 people. Eli Lilly and Company CEO is David A. Ricks.

The one-year performance of Eli Lilly and Company stock is 43.66%, while year-to-date (YTD) performance is 24.68%. LLY stock has a five-year performance of 92.6%. Its 52-week range is between 101.36 and 167.43, which gives LLY stock a 52-week price range ratio of 94.61%

Eli Lilly and Company currently has a PE ratio of 26.90, a price-to-book (PB) ratio of 50.58, a price-to-sale (PS) ratio of 6.74, a price to cashflow ratio of 30.40, a PEG ratio of 2.32, a ROA of 13.99%, a ROC of 29.74% and a ROE of 199.07%. The company’s profit margin is 23.97%, its EBITDA margin is 33.70%, and its revenue ttm is $23.09 Billion , which makes it $24.14 revenue per share.

Of the last four earnings reports from Eli Lilly and Company, there were 4 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $1.58 for the next earnings report. Eli Lilly and Company’s next earnings report date is 30th Jul 2020.

The consensus rating of Wall Street analysts for Eli Lilly and Company is Moderate Buy (1.67), with a target price of $173.5, which is +5.88% compared to the current price. The earnings rating for Eli Lilly and Company stock is Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Eli Lilly and Company has a dividend yield of 1.82% with a dividend per share of $2.96 and a payout ratio of 52.00%.

Eli Lilly and Company has a Buy technical analysis rating based on Technical Indicators (ADX : 23.69, ATR14 : 4.58, CCI20 : 73.29, Chaikin Money Flow : -0.02, MACD : 3.14, Money Flow Index : 62.42, ROC : 2.44, RSI : 60.93, STOCH (14,3) : 87.17, STOCH RSI : 0.88, UO : 60.00, Williams %R : -12.83), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Eli Lilly and Company in the last 12-months were: Aarti S. Shah (Sold 2 000 shares of value $300 000 ), Alfonso G. Zulueta (Option Excercise at a value of $0), Alfonso G. Zulueta (Sold 75 000 shares of value $9 740 960 ), Anne Nobles (Buy at a value of $108 840), Daniel Skovronsky (Buy at a value of $543 050), David A. Ricks (Buy at a value of $500 174), David A. Ricks (Option Excercise at a value of $0), Donald A. Zakrowski (Sold 3 700 shares of value $473 600 ), Jackson P. Tai (Buy at a value of $200 039), Johna L. Norton (Option Excercise at a value of $0), Johna L. Norton (Sold 4 727 shares of value $619 237 ), Joshua Smiley (Buy at a value of $120 018), Melissa S. Barnes (Option Excercise at a value of $0), Myles O'Neill (Sold 50 000 shares of value $6 503 750 ), Stephen Fry (Option Excercise at a value of $0), Stephen Fry (Sold 24 109 shares of value $3 055 414 )

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
6 (66.67 %)
6 (66.67 %)
7 (77.78 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
3 (33.33 %)
3 (33.33 %)
2 (22.22 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingModerate Buy
1.67
Moderate Buy
1.67
Strong Buy
1.44

Eli Lilly and Company

Eli Lilly is a pharmaceutical company with a focus on neuroscience, endocrinology, oncology, and immunology. Lilly's key products include Alimta and Verzenio for cancer; Forteo for osteoporosis; Jardiance, Trulicity, Humalog, and Humulin for diabetes; Taltz and Olumiant for immunology; and Cialis for erectile dysfunction.

CEO: David A. Ricks

Teplephone: +1 317 276-2000

Address: Lilly Corporate Center, Indianapolis 46285, IN, USA

Number of employees: 38 680

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

100%0%

Bearish Bullish

55%45%

Bearish Bullish

45%55%

Bearish Bullish

52%48%

News

Stocktwits